ES2641869T3 - Polipéptidos de fusión de leptina-ABD con duración de acción aumentada - Google Patents
Polipéptidos de fusión de leptina-ABD con duración de acción aumentada Download PDFInfo
- Publication number
- ES2641869T3 ES2641869T3 ES11833080.2T ES11833080T ES2641869T3 ES 2641869 T3 ES2641869 T3 ES 2641869T3 ES 11833080 T ES11833080 T ES 11833080T ES 2641869 T3 ES2641869 T3 ES 2641869T3
- Authority
- ES
- Spain
- Prior art keywords
- leptin
- comp
- seq
- action
- fusion polypeptides
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Reproductive Health (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Gynecology & Obstetrics (AREA)
- Hospice & Palliative Care (AREA)
- Pregnancy & Childbirth (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
ausente (SEQ ID NO:2)
VPICKVQDDTKTLIKTIVTRINDISHT-Xaa-SVSSKQRVTGLDFIPGLHPLLSLSKMDQTLAI YQQILTSLPSRNVVQISNDLENLRDLLHLLAASKSCPLPQVRALESLESLGWLEASLYST EVVALSRLQGSLQDMLRQLDLSPGC, en las que Xaa en la posición 28 es Q o está ausente (SEQ ID
VPIQKVQDDTKTLIKTIVTRINDISHT-Xaa-SVSSKQKVTGLDFIPGLHPILTLSKMDQTLA
25 VYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPQASGLETLESLGGVLEASGY STEVVALSRLQGSLQDMLQQLDLSPGC, en las que Xaa en la posición 29 es Q o está ausente (SEQ ID NO: 6).
35 eliminada): VPIQKVQDDTKTLIKTIVTRINDISH-Xaa-Xaa-SVSSKQKVTGLDFIPGLHPILTLSKMDQT LAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEAS GYSTEVVALSRLQGSLQDMLWQLDLSPGC, en las que: Xaa en la posición 27 es T o A; y Xaa en la posición 28 es Q o está ausente (SEQ ID NO:8).
40
Leptinas humanas maduras con metionina en el extremo N:
MVPIQKVQDDTKTLIKTIVTRINDISH-Xaa-Xaa-SVSSKQKVTGLDFIPGLHPILTLSKMDQ TLAVYQQILTSMPSRNVIQISNDLENLRDLLHVLAFSKSCHLPWASGLETLDSLGGVLEA SGYSTEVVALSR
8
resto de PEG de 40 kDa mediante el extremo N.
Resultados. Tal como se establece en la Tabla 6 siguiente, los polipéptidos diseñados mediante ingeniería genética descritos en el presente documento (por ejemplo, Comps. 1-4) tiene una actividad funcional, e incluso superior, en el ensayo Obeca STAT5, en comparación con varias leptinas conjugadas.
Tabla 6: Actividad funcional in vitro de las leptinas
- Comp.
- Tipo de molécula o polipéptido diseñado por ingeniería genética CE50 nM (ensayo Obeca STAT5)
- C1
- SEQ ID NO:20 0,038
- C2
- SEQ ID NO: 30 0,855
- C3
- SEQ ID NO:32 -único PEG de 20 kDa mediante 78C 0,319
- C4
- SEQ ID NO:20 -único PEG de 20 kDa mediante el extremo N 0,275
- C5
- SEQ ID NO:32 PEGilado doble (20kDa PEG mediante 78C y PEG de 20 kDa mediante el extremo N) 2,262
- C6
- SEQ ID NO:20 -único PEG de 40 kDa mediante en el extremo N 0,355
- 1
- SEQ ID NO:53 0,628
- 2
- SEQ ID NO:54 0,530
- 3
- SEQ ID NO:55 0,095
- 4
- SEQ ID NO:56 0,103
- 9
- SEQ ID NO:57 0,185
- 12
- SEQ ID NO:58 1,052
- 13
- SEQ ID NO:59 0,116
- 14
- SEQ ID NO:60 0,406
- 15
- SEQ ID NO:61 0,427
- 16
- SEQ ID NO:62 0,411
- 17
- SEQ ID NO:63 0,468
- 18
- SEQ ID NO:64 0,322
Ejemplo 3: Cambio en el peso corporal después de una sola administración.
10 Método. Ratas Sprague Dawley magras se mantuvieron con una dieta baja en grasa durante el estudio. El peso corporal medio fue 319 gramos al comienzo del estudio. Los animales se dividieron en seis grupos (n=6/grupo). Cada grupo fue asignado para recibir uno de los siguientes: vehículo; Comp. 1 a 2,6 mg/kg en vehículo; Comp. 2 a 2,7 mg/kg en vehículo; Comp. 4 a 2,7 mg/kg en vehículo; Comp. 2 a 10 mg/kg en vehículo. Cada animal de ensayo
15 recibió una única inyección subcutánea a tiempo=0. La ingesta de alimento y el cambio en el peso corporal (corregido para el % de vehículo) se controlaron durante 14 días, y los resultados se registraron como se muestra (Figuras 1A a 1B). Compuestos administrados: Vehículo (en recuadro); Comp. 1 a 2,6 mg/kg (triángulo con la punta hacia arriba); Comp. 2 a 2,7 mg/kg (triángulo con la punta hacia abajo); Comp. 4 a 2,7 mg/kg (rombo); Comp. C2 a 10 mg/kg (círculo).
20 Resultados. Tal como se representa gráficamente en las Figuras 1A a 1B, la administración de cada polipéptido diseñado por ingeniería genética dio como resultado una reducción de la ingesta de alimento y peso corporal. Todos los compuestos se proporcionaron en una dosis equimolar por peso de compuesto; todos los compuestos se proporcionaron a 120 nmol/kg (es decir, Comp. 1 a 2,6 mg/kg; Comp. 2 y Comp. 4 a 2,7 mg/kg; Comp. C2 a 10
25 mg/kg). Se debe indicar que el Comp. C2 (es decir, A200) es un dímero de dos restos, comprendiendo cada resto la región FC de IgG1 fusionada a leptina humana. El Comp. 1 y el Comp. 2 tienen una actividad similar al Comp. C2 que, por ser un dímero, tiene realmente dos leptinas por molécula. Aunque la eficacia (disminución del peso corporal) parece similar, es evidente que la tendencia favorece ambos polipéptidos diseñados por ingeniería genética con respecto al Comp. C2. Cuando se mira en una base molar de leptina, los polipéptidos diseñados
30 mediante ingeniería genética son superiores para la inhibición tanto de la ingesta de alimento como del peso corporal, ya que el Comp. C2 tiene 2 moles de leptina en cada complejo Fc-leptina dimérico, mientras que cada mol de ABD-resto de leptina tiene solamente 1 mol de leptina.
Resultados anteriores han demostrado que se necesitan aproximadamente 500 ug/kg/día de un compuesto A500
35 para conseguir una pérdida de peso de 9-10 % a los 7 días cuando se administra mediante infusión continua a una rata magra. Esto da como resultado 2,5 mg de compuesto de leptina A500 a los 5 días y de 3,5 mg de compuesto a los 7 días. Puesto que el propio compuesto A500 tiene 16067,68 g/mol y el peso molecular del Comp. 2 es ∼22.510 g/mol, se anticiparía la necesidad de 1,4X más veces proteína de fusión ABD durante los 5 días. En su lugar, solamente se administró 1,08x (2,7 mg/2,5 mg) más compuesto, lo que indica una sorprendente propiedad que
40 ahorra dosis.
63
Ejemplo 20: Estabilidad de los polipéptidos diseñados mediante ingeniería genética
Tal como se establece en la Tabla 9 siguiente, los polipéptidos diseñados mediante ingeniería genética descritos en
5 el presente documento son químicamente estables. Los compuestos se formularon a 1 mg/ml en tampones de diferentes pH. Como se muestra en la Tabla 9, los polipéptidos quiméricos tienen buena potencia (Tabla 9A) y pureza (Tabla 9B) después de dos semanas a 40°C, como se determina mediante cromatografía líquida de alto rendimiento (HPLC) en fase invertida.
- Compuesto
- % Potencia* según HPLC de fase invertida, 14 días a 40°C
- pH 3,0
- pH 4,0 pH 5,0 pH 6,0 pH 7,0 pH 8,0 pH 9,0 PBS, pH 7,4
- ABD1-HuSeal (Comp. 15)
- 102,7 107,2 104,9 108,5 107,3 100,1 90,7 104,5
- ABD1-A500 (Comp. 2)
- 95,9 95,9 97,3 91,7 87,3 90,8 72,1 92,0
- ABD1-A100 (SEQ ID NO:147)
- 72,3 82,0 88,8 86,1 83,3 85,8 69,6 89,2
* Potencia = área del pico principal/área nor. ref. Tabla 9B. Pureza de los polipéptidos diseñados mediante ingeniería genética
- Compuesto
- % Pureza según HPLC de fase invertida, 14 días a 40°C
- pH 3,0
- pH 4,0 pH 5,0 pH 6,0 pH 7,0 pH 8,0 pH 9,0 PBS, pH 7,4
- ABD1-HuSeal
- 96,7 98,0 98,5 99,8 97,6 93,8 95,1 97,1
- ABD1-A500
- 94,9 96,2 96,8 97,3 96,9 97,5 82,7 97,4
- ABD 1-A100
- 70,0 79,4 85,4 86,5 86,8 86,8 70,9 87,8
Tal como se establece en la Tabla 10 siguiente, los polipéptidos diseñados mediante ingeniería genética descritos en el presente documento son químicamente estables. El Compuesto 15 se formuló a tres concentraciones diferentes en el siguiente tampón: ácido glutámico 10 mM, glicina al 2 %, sacarosa al 1 %, Tween 20 al 0,01 %, pH 4,25 y se
20 almacenó a 5°C, 15°C, o 25°C. Como se muestra en la Tabla 10, el Compuesto 15 es químicamente estable a 10, 20, y 30 mg/ml durante al menos 1 mes a 5-25°C, según se determina mediante HPLC.
Tabla 10. Estabilidad de los polipéptidos diseñados mediante ingeniería genética
- Concentración (mg/ml)
- Condiciones de almacenamiento (0C) % de potencia mediante RP-HPLC en un punto temporal (semana)
- 0
- 2 4
- 5
- 103,1 103,6 103,1
- 10
- 15 103,1 102,7 102,0
- 25
- 103,1 103,8 104,0
- 5
- 102,0 103,6 103,7
- 20
- 15 102,0 103,6 104,1
- 25
- 102,0 103,2 103,8
- 5
- 104,1 104,1 103,3
- 30
- 15 104,1 103,7 104,0
- 25
- 104,1 102,6 103,4
- Concentración (mg/ml)
- Condiciones de almacenamiento (0C) % Pureza mediante SCX-HPLC en un punto temporal (semana)
- 0
- 2 4
- 10
- 5 97,6 97,3 97,7
- 15
- 97,6 97,6 97,5
- 25
- 97,6 97,4 96,0
- 5
- 97,9 97,7 97,6
- 20
- 15 97,9 97,6 97,7
- 25
- 97,9 97,4 96,4
- 5
- 97,7 97,6 97,7
- 30
- 15 97,7 97,7 97,6
- 25
- 97,7 97,3 97,2
25 Ejemplo 22: Estabilidad de los polipéptidos diseñados mediante ingeniería genética Tal como se establece en la Tabla 11 siguiente, los polipéptidos diseñados mediante ingeniería genética descritos en el presente documento son físicamente estables. El Compuesto 15 se formuló a tres concentraciones diferentes en
68
Claims (1)
-
imagen1 imagen2 imagen3 imagen4
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US38740210P | 2010-09-28 | 2010-09-28 | |
US387402P | 2010-09-28 | ||
US42209110P | 2010-12-10 | 2010-12-10 | |
US422091P | 2010-12-10 | ||
PCT/US2011/053786 WO2012050930A2 (en) | 2010-09-28 | 2011-09-28 | Engineered polypeptides having enhanced duration of action |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2641869T3 true ES2641869T3 (es) | 2017-11-14 |
Family
ID=45938879
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11833075.2T Active ES2630031T3 (es) | 2010-09-28 | 2011-09-28 | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
ES17163203T Active ES2873253T3 (es) | 2010-09-28 | 2011-09-28 | Leptinas altamente solubles |
ES11833080.2T Active ES2641869T3 (es) | 2010-09-28 | 2011-09-28 | Polipéptidos de fusión de leptina-ABD con duración de acción aumentada |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES11833075.2T Active ES2630031T3 (es) | 2010-09-28 | 2011-09-28 | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
ES17163203T Active ES2873253T3 (es) | 2010-09-28 | 2011-09-28 | Leptinas altamente solubles |
Country Status (14)
Country | Link |
---|---|
US (6) | US20130203661A1 (es) |
EP (4) | EP3241558B1 (es) |
JP (5) | JP2014502252A (es) |
CN (2) | CN103547590B (es) |
BR (3) | BR122021020041B1 (es) |
CA (3) | CA2813087C (es) |
CY (2) | CY1119023T1 (es) |
DK (3) | DK3241558T3 (es) |
EA (2) | EA032917B1 (es) |
ES (3) | ES2630031T3 (es) |
MX (2) | MX351128B (es) |
PL (1) | PL3241558T3 (es) |
PT (2) | PT2621519T (es) |
WO (2) | WO2012050925A2 (es) |
Families Citing this family (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ604805A (en) | 2010-07-09 | 2014-09-26 | Affibody Ab | Polypeptides |
ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
DK2729160T3 (da) * | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
WO2013148966A1 (en) * | 2012-03-28 | 2013-10-03 | Amylin Pharmaceuticals, Llc | Transmucosal delivery of engineered polypeptides |
JP6590695B2 (ja) * | 2012-09-25 | 2019-10-16 | アフィボディ・アーベー | アルブミン結合ポリペプチド |
CA2908198A1 (en) | 2013-04-18 | 2014-10-23 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
US9823255B2 (en) | 2013-06-17 | 2017-11-21 | Armo Biosciences, Inc. | Method for assessing protein identity and stability |
AU2014311432A1 (en) | 2013-08-30 | 2016-03-03 | Armo Biosciences, Inc. | Methods of using interleukin-10 for treating diseases and disorders |
MX2016005915A (es) | 2013-11-11 | 2016-12-16 | Armo Biosciences Inc | Metodos de uso de interleucina-10 para tratar enfermedades y trastornos. |
US10167322B2 (en) | 2013-12-20 | 2019-01-01 | Affibody Ab | Engineered albumin binding polypeptide |
CN106573072A (zh) | 2014-06-02 | 2017-04-19 | 阿尔莫生物科技股份有限公司 | 降低血清胆固醇的方法 |
AR101742A1 (es) | 2014-09-04 | 2017-01-11 | Novo Nordisk As | Agonista del receptor de calcitonina y amilina |
CN107001438A (zh) | 2014-10-14 | 2017-08-01 | 阿尔莫生物科技股份有限公司 | 白细胞介素‑15组合物及其用途 |
CN107106655A (zh) | 2014-10-22 | 2017-08-29 | 阿尔莫生物科技股份有限公司 | 使用白细胞介素‑10治疗疾病和病症的方法 |
US10618970B2 (en) | 2015-02-03 | 2020-04-14 | Armo Biosciences, Inc. | Method of treating cancer with IL-10 and antibodies that induce ADCC |
EP3302547A1 (en) | 2015-05-28 | 2018-04-11 | Armo Biosciences, Inc. | Pegylated interleukin-10 for use in treating cancer |
US11643439B2 (en) | 2015-08-05 | 2023-05-09 | Shaanxi Micot Technology Limited Company | Multi-target compound with anticoagulation and antiplatelet activity, preparation method therefor, and use thereof |
US10286079B2 (en) | 2015-09-22 | 2019-05-14 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
WO2017053391A1 (en) | 2015-09-22 | 2017-03-30 | The Regents Of The University Of California | Modified cytotoxins and their therapeutic use |
AU2016332352A1 (en) | 2015-10-02 | 2018-04-12 | Memorial Sloan-Kettering Cancer Center | Small molecules blocking histone reader domains |
PT3509624T (pt) | 2016-09-12 | 2023-08-28 | Amryt Pharmaceuticals Inc | Métodos de deteção de anticorpos neutralizantes anti-leptina |
EP3573661A4 (en) * | 2017-01-30 | 2020-08-12 | Alexion Pharmaceuticals, Inc. | MONOVALENT ANTI-PROPERDINE ANTIBODIES AND ANTIBODY FRAGMENTS |
EP3773461A4 (en) * | 2018-04-13 | 2022-02-09 | Massachusetts Institute of Technology | MODIFIED TREATMENTS FOR HAIR REPAIR AND LASTING COLOR RETENTION |
WO2023049357A2 (en) * | 2021-09-24 | 2023-03-30 | The Uab Research Foundation | Control of subunit stoichiometry in single-chain msp nanopores |
Family Cites Families (156)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
US4572208A (en) | 1983-06-29 | 1986-02-25 | Utah Medical Products, Inc. | Metabolic gas monitoring apparatus and method |
US4703008A (en) | 1983-12-13 | 1987-10-27 | Kiren-Amgen, Inc. | DNA sequences encoding erythropoietin |
NZ210501A (en) | 1983-12-13 | 1991-08-27 | Kirin Amgen Inc | Erythropoietin produced by procaryotic or eucaryotic expression of an exogenous dna sequence |
KR850004274A (ko) | 1983-12-13 | 1985-07-11 | 원본미기재 | 에리트로포이에틴의 제조방법 |
US6319685B1 (en) | 1984-09-27 | 2001-11-20 | Unigene Laboratories, Inc. | Alpha-amidating enzyme compositions and processes for their production and use |
FI78231C (fi) | 1984-11-21 | 1989-07-10 | Instrumentarium Oy | Maetanordning foer metaboliska storheter anslutbar till en respirator. |
US4695463A (en) | 1985-05-24 | 1987-09-22 | Warner-Lambert Company | Delivery system for active ingredients and preparation thereof |
US4766106A (en) | 1985-06-26 | 1988-08-23 | Cetus Corporation | Solubilization of proteins for pharmaceutical compositions using polymer conjugation |
US4810643A (en) | 1985-08-23 | 1989-03-07 | Kirin- Amgen Inc. | Production of pluripotent granulocyte colony-stimulating factor |
JPS63500636A (ja) | 1985-08-23 | 1988-03-10 | 麒麟麦酒株式会社 | 多分化能性顆粒球コロニー刺激因子をコードするdna |
US4904584A (en) | 1987-12-23 | 1990-02-27 | Genetics Institute, Inc. | Site-specific homogeneous modification of polypeptides |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
WO1990006952A1 (en) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Chemically modified granulocyte colony stimulating factor |
US5166322A (en) | 1989-04-21 | 1992-11-24 | Genetics Institute | Cysteine added variants of interleukin-3 and chemical modifications thereof |
RU2212411C2 (ru) | 1989-10-16 | 2003-09-20 | Эмджен Инк. | Полипептид, обладающий гемопоэтической биологической активностью фактора стволовых клеток (варианты), днк (варианты), экспрессирующий вектор (варианты), фармацевтическая композиция для гемопоэтической терапии, способ получения полипептида и способ его использования (варианты) |
US5372808A (en) | 1990-10-17 | 1994-12-13 | Amgen Inc. | Methods and compositions for the treatment of diseases with consensus interferon while reducing side effect |
HU222249B1 (hu) | 1991-03-08 | 2003-05-28 | Amylin Pharmaceuticals Inc. | Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására |
JP3213314B2 (ja) | 1991-04-05 | 2001-10-02 | ボード・オブ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・ワシントン | 幹細胞因子レセプターに対するモノクローナル抗体 |
NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
US5912015A (en) | 1992-03-12 | 1999-06-15 | Alkermes Controlled Therapeutics, Inc. | Modulated release from biocompatible polymers |
US5581476A (en) | 1993-01-28 | 1996-12-03 | Amgen Inc. | Computer-based methods and articles of manufacture for preparing G-CSF analogs |
US5766627A (en) | 1993-11-16 | 1998-06-16 | Depotech | Multivescular liposomes with controlled release of encapsulated biologically active substances |
US6288030B1 (en) | 1993-12-22 | 2001-09-11 | Amgen Inc. | Stem cell factor formulations and methods |
US6048837A (en) | 1994-08-17 | 2000-04-11 | The Rockefeller University | OB polypeptides as modulators of body weight |
US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
US5563243A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
CA2211664A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Anti-obesity proteins |
US5554727A (en) | 1995-01-31 | 1996-09-10 | Eli Lilly And Company | Anti-obesity proteins |
US5574133A (en) | 1995-01-31 | 1996-11-12 | Eli Lilly And Company | Anti-obesity proteins |
AU4766096A (en) | 1995-01-31 | 1996-08-21 | Eli Lilly And Company | Anti-obesity proteins |
US5569743A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
US5569744A (en) | 1995-01-31 | 1996-10-29 | Eli Lilly And Company | Anti-obesity proteins |
US5525705A (en) | 1995-01-31 | 1996-06-11 | Eli Lilly And Company | Anti-obesity proteins |
US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5563245A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
US5567678A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
US5559208A (en) | 1995-01-31 | 1996-09-24 | Eli Lilly And Company | Anti-obesity proteins |
US5605886A (en) | 1995-01-31 | 1997-02-25 | Eli Lilly And Company | Anti-obesity proteins |
US5691309A (en) | 1995-01-31 | 1997-11-25 | Eli Lilly And Company | Anti-obesity proteins |
US5563244A (en) | 1995-01-31 | 1996-10-08 | Eli Lilly And Company | Anti-obesity proteins |
US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
WO1996023815A1 (en) | 1995-01-31 | 1996-08-08 | Eli Lilly And Company | Ob gene product antibodies |
US5567803A (en) | 1995-01-31 | 1996-10-22 | Eli Lilly And Company | Anti-obesity proteins |
US5594104A (en) | 1995-01-31 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
US5580954A (en) | 1995-01-31 | 1996-12-03 | Eli Lilly And Company | Anti-obesity proteins |
US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
US5594101A (en) | 1995-03-03 | 1997-01-14 | Eli Lilly And Company | Anti-obesity proteins |
US5719266A (en) | 1995-03-17 | 1998-02-17 | Eli Lilly And Company | Anti-obesity proteins |
EP0736599A3 (en) | 1995-04-03 | 1996-12-11 | Takeda Chemical Industries Ltd | The rat obesity gene, its gene product and its production |
AU5539596A (en) | 1995-04-06 | 1996-10-23 | Amylin Pharmaceuticals, Inc. | Anti-obesity agents |
US5840517A (en) * | 1995-04-26 | 1998-11-24 | Eli Lilly And Company | Process for preparing obesity protein analogs |
US5614379A (en) | 1995-04-26 | 1997-03-25 | Eli Lilly And Company | Process for preparing anti-obesity protein |
DE741187T1 (de) | 1995-05-05 | 1997-04-30 | Hoffmann La Roche | Rekombinante Obesitäts-(OB)-Proteine |
GB9509164D0 (en) | 1995-05-05 | 1995-06-28 | Smithkline Beecham Plc | Novel compounds |
EP0826045A1 (en) | 1995-05-08 | 1998-03-04 | Chiron Corporation | Nucleic acids for treating obesity |
EP0744408A3 (en) | 1995-05-26 | 1997-01-02 | Eli Lilly And Company | Rhesus ob protein and DNA |
AU6028396A (en) | 1995-06-07 | 1996-12-30 | Amgen, Inc. | Ob protein compositions and method |
US5581005A (en) | 1995-06-16 | 1996-12-03 | The Procter & Gamble Company | Method for manufacturing cobalt catalysts |
AU6284896A (en) | 1995-06-22 | 1997-01-22 | Eli Lilly And Company | Obesity protein intermediates and their preparation and use |
GB2302559B (en) | 1995-06-23 | 1998-06-03 | Draftex Ind Ltd | Opening arrangements and methods for closure members |
EP0835101B1 (en) | 1995-06-27 | 2004-06-09 | Takeda Chemical Industries, Ltd. | Method of producing sustained-release preparation |
EP0836479A2 (en) * | 1995-06-30 | 1998-04-22 | Eli Lilly And Company | Methods for treating diabetes |
PT865294E (pt) | 1995-08-17 | 2004-07-30 | Amgen Inc | Processo para a reducao ou a manutencao de niveis reduzidos de lipidos no sangue utilizando composicoes de proteina ob |
WO1997016550A1 (en) | 1995-11-02 | 1997-05-09 | Bristol-Myers Squibb Company | Polypeptide fragments derived from the obese gene product |
US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
ES2217327T3 (es) | 1995-11-22 | 2004-11-01 | Amgen Inc., | Proteina ob para aumentar la masa de tejido magro. |
AU1406497A (en) | 1995-12-06 | 1997-06-27 | Schering Corporation | Mutational variants of mammalian ob gene proteins |
US6369027B1 (en) | 1995-12-22 | 2002-04-09 | Amgen Inc. | Osteoprotegerin |
GB9526733D0 (en) * | 1995-12-30 | 1996-02-28 | Delta Biotechnology Ltd | Fusion proteins |
AU2246097A (en) | 1996-01-25 | 1997-08-20 | Eli Lilly And Company | Obesity protein analog compounds and formulations thereof |
US6013009A (en) | 1996-03-12 | 2000-01-11 | Karkanen; Kip Michael | Walking/running heart rate monitoring system |
AU2670897A (en) | 1996-04-04 | 1997-10-29 | Amgen, Inc. | Fibulin pharmaceutical compositions and related methods |
US6025324A (en) | 1996-05-15 | 2000-02-15 | Hoffmann-La Roche Inc. | Pegylated obese (ob) protein compositions |
AR008765A1 (es) | 1996-06-06 | 2000-02-23 | Smithkline Beecham Plc | Un peptido o un derivado, analogo o variante, funcional del mismo, un peptido recombinante o sintetico del mismo, una secuencia nucleotidica y vectorque la contiene, una celula huesped transformada, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un compuesto del |
US5922678A (en) | 1996-06-28 | 1999-07-13 | Eli Lilly And Company | Methods for treating diabetes |
CA2263826A1 (en) | 1996-08-30 | 1998-03-05 | Amgen Inc. | Methods of increasing sensitivity of an individual to ob protein by upregulating ob protein receptor |
CA2266585A1 (en) | 1996-09-20 | 1998-03-26 | Hoechst Aktiengesellschaft | Use of leptin antagonists for treating insulin resistance in type ii diabetes |
AU4582597A (en) | 1996-10-11 | 1998-05-11 | Eli Lilly And Company | Therapeutic proteins |
AU5654998A (en) | 1996-12-06 | 1998-06-29 | F. Hoffmann-La Roche Ag | Muteins of obese protein |
EA004790B1 (ru) | 1996-12-20 | 2004-08-26 | Амген Инк. | Композиции на основе слитого белка ов и способы их применения |
US6309360B1 (en) | 1997-03-17 | 2001-10-30 | James R. Mault | Respiratory calorimeter |
AU6569998A (en) * | 1997-03-20 | 1998-10-12 | Eli Lilly And Company | Obesity protein formulations |
JP2002504102A (ja) | 1997-06-06 | 2002-02-05 | スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー | 糖尿病治療のためのレプチン拮抗物質の使用 |
DE69837170T2 (de) | 1997-06-13 | 2007-11-22 | Amylin Pharmaceuticals, Inc., San Diego | Festphasige native chemische Ligation von ungeschützten oder n-cystein-geschützten Peptiden in wässrigen Lösungen |
AU753205B2 (en) | 1998-05-29 | 2002-10-10 | Catalysts & Chemicals Industries Co., Ltd. | Method of manufacturing photoelectric cell and oxide semiconductor for photoelectric cell |
ES2228082T3 (es) | 1998-08-10 | 2005-04-01 | Amgen Inc. | Conjugados dextrano-leptina, composiciones farmaceuticas y metodos relacionados. |
JP2002526780A (ja) | 1998-10-02 | 2002-08-20 | アムジエン・インコーポレーテツド | レプチン処置に対する素因の決定方法 |
US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6194006B1 (en) | 1998-12-30 | 2001-02-27 | Alkermes Controlled Therapeutics Inc. Ii | Preparation of microparticles having a selected release profile |
ES2278589T3 (es) | 1999-01-14 | 2007-08-16 | Amylin Pharmaceuticals, Inc. | Excendinas destinadas a la inhibicion de glucagon. |
WO2000047741A1 (en) | 1999-02-12 | 2000-08-17 | Amgen Inc. | Glycosylated leptin compositions and related methods |
US6475984B2 (en) * | 1999-04-29 | 2002-11-05 | The Nemours Foundation | Administration of leptin |
TW514510B (en) | 1999-06-11 | 2002-12-21 | Tanita Seisakusho Kk | Method and apparatus for measuring distribution of body fat |
US6468222B1 (en) | 1999-08-02 | 2002-10-22 | Healthetech, Inc. | Metabolic calorimeter employing respiratory gas analysis |
US6258932B1 (en) | 1999-08-09 | 2001-07-10 | Tripep Ab | Peptides that block viral infectivity and methods of use thereof |
EP1214351A2 (en) * | 1999-09-22 | 2002-06-19 | Genset | Methods of screening for compounds that modulate the lsr-leptin interaction and their use in the prevention and treatment of obesity-related diseases |
US6530886B1 (en) | 1999-10-08 | 2003-03-11 | Tanita Corporation | Method and apparatus for measuring subcutaneous fat using ultrasonic wave |
US7057015B1 (en) * | 1999-10-20 | 2006-06-06 | The Salk Institute For Biological Studies | Hormone receptor functional dimers and methods of their use |
HUP0203837A2 (hu) | 1999-11-10 | 2003-03-28 | Takeda Chemical Industries, Ltd. | Testtömegnövekedést gátló szerek |
JP2001199887A (ja) | 1999-11-10 | 2001-07-24 | Takeda Chem Ind Ltd | 体重増加抑制剤 |
US20050287153A1 (en) * | 2002-06-28 | 2005-12-29 | Genentech, Inc. | Serum albumin binding peptides for tumor targeting |
US7157564B1 (en) | 2000-04-06 | 2007-01-02 | Affymetrix, Inc. | Tag nucleic acids and probe arrays |
JP2003530838A (ja) * | 2000-04-12 | 2003-10-21 | ヒューマン ゲノム サイエンシズ インコーポレイテッド | アルブミン融合タンパク質 |
US6264987B1 (en) | 2000-05-19 | 2001-07-24 | Alkermes Controlled Therapeutics Inc. Ii | Method for preparing microparticles having a selected polymer molecular weight |
TW515705B (en) | 2000-05-31 | 2003-01-01 | Yamato Scale Co Ltd | Visceral fat meter |
US6492117B1 (en) | 2000-07-12 | 2002-12-10 | Gendaq Limited | Zinc finger polypeptides capable of binding DNA quadruplexes |
US6296842B1 (en) | 2000-08-10 | 2001-10-02 | Alkermes Controlled Therapeutics, Inc. | Process for the preparation of polymer-based sustained release compositions |
US6475158B1 (en) | 2000-10-24 | 2002-11-05 | Korr Medical Technologies, Inc. | Calorimetry systems and methods |
DK1444516T3 (da) | 2001-10-22 | 2010-11-15 | Amgen Inc | Anvendelse af leptin til behandling af lipoatrofi hos mennesker og fremgangsmåde til at bestemme en prædisposition for denne behandling |
US6899892B2 (en) | 2001-12-19 | 2005-05-31 | Regents Of The University Of Minnesota | Methods to reduce body fat |
CA2471363C (en) | 2001-12-21 | 2014-02-11 | Human Genome Sciences, Inc. | Albumin fusion proteins |
WO2004039832A2 (en) | 2002-10-31 | 2004-05-13 | Albany Medical College | Leptin-related peptides |
JPWO2004039853A1 (ja) | 2002-11-01 | 2006-03-02 | 株式会社トクヤマ | 重合性組成物、その硬化体の製造法および光学物品 |
TW200522976A (en) * | 2003-09-19 | 2005-07-16 | Novo Nordisk As | Novel plasma protein affinity tags |
CA2539253A1 (en) * | 2003-09-19 | 2005-03-31 | Novo Nordisk A/S | Albumin-binding derivatives of therapeutic peptides |
US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
WO2006083254A1 (en) | 2004-02-11 | 2006-08-10 | Amylin Pharmaceuticals, Inc. | Amylin family peptides and methods for making and using them |
US7399744B2 (en) | 2004-03-04 | 2008-07-15 | Amylin Pharmaceuticals, Inc. | Methods for affecting body composition |
WO2009100255A2 (en) * | 2008-02-08 | 2009-08-13 | Ambrx, Inc. | Modified leptin polypeptides and their uses |
US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
AU2005311099B2 (en) | 2004-12-02 | 2012-02-02 | Domantis Limited | Bispecific domain antibodies targeting serum albumin and GLP-1 or PYY |
US7898623B2 (en) | 2005-07-04 | 2011-03-01 | Semiconductor Energy Laboratory Co., Ltd. | Display device, electronic device and method of driving display device |
GB0524788D0 (en) * | 2005-12-05 | 2006-01-11 | Affibody Ab | Polypeptides |
EP1976873A2 (en) | 2006-01-11 | 2008-10-08 | Brystol-Myers Squibb Company | Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions |
CN101400698A (zh) | 2006-03-15 | 2009-04-01 | 诺沃-诺迪斯克有限公司 | 胰岛淀粉样多肽衍生物 |
EP2010208A1 (en) | 2006-03-31 | 2009-01-07 | Amylin Pharmaceuticals, Inc. | Amylin and amylin agonists for treating psychiatric diseases and disorders |
AU2007267833B2 (en) | 2006-05-26 | 2012-07-26 | Amylin Pharmaceuticals, Llc | Composition and methods for treatment of congestive heart failure |
WO2007139589A1 (en) | 2006-05-26 | 2007-12-06 | Bristol-Myers Squibb Company | Sustained release glp-1 receptor modulators |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
CN101113175A (zh) * | 2007-04-28 | 2008-01-30 | 中国科学院西北高原生物研究所 | 鼠兔家族瘦素蛋白及其cDNA序列 |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
ES2346178T3 (es) | 2007-07-31 | 2015-11-02 | Affibody Ab | Nuevas composiciones, procedimientos y usos de unión de la albúmina |
GB0715216D0 (en) | 2007-08-03 | 2007-09-12 | Asterion Ltd | Leptin |
EP2036923A1 (en) | 2007-09-11 | 2009-03-18 | Novo Nordisk A/S | Improved derivates of amylin |
WO2009042922A2 (en) * | 2007-09-27 | 2009-04-02 | Amylin Pharmaceuticals, Inc. | Peptide-peptidase inhibitor conjugates and methods of making and using same |
EA201070609A1 (ru) | 2007-11-14 | 2010-12-30 | Амилин Фармасьютикалз, Инк. | Способы лечения ожирения и ассоциированных с ожирением заболеваний и расстройств |
WO2009149379A2 (en) | 2008-06-05 | 2009-12-10 | Regents Of The University Of Michigan | Use of leptin for the treatment of fatty liver diseases and conditions |
EP2340261B1 (en) | 2008-10-21 | 2017-12-20 | Novo Nordisk A/S | Amylin derivatives |
WO2010054699A1 (en) * | 2008-11-17 | 2010-05-20 | Affibody Ab | Conjugates of albumin binding domain |
CN102292346B (zh) | 2009-01-22 | 2015-12-02 | 关键生物科学有限公司 | 肥胖的治疗 |
ES2730800T3 (es) | 2009-02-03 | 2019-11-12 | Amunix Pharmaceuticals Inc | Polipéptidos recombinantes extendidos y composiciones que comprenden los mismos |
MX348567B (es) * | 2010-06-04 | 2017-06-20 | Tiumbio Co Ltd | Proteina de fusion que tiene actividad de factor vii. |
NZ604805A (en) | 2010-07-09 | 2014-09-26 | Affibody Ab | Polypeptides |
EP2621538B1 (en) | 2010-09-28 | 2015-12-16 | Amylin Pharmaceuticals, LLC | Engineered polypeptides having enhanced duration of action |
ES2630031T3 (es) | 2010-09-28 | 2017-08-17 | Aegerion Pharmaceuticals, Inc. | Un polipéptido de leptina pinnípedo-humano quimérico con solubilidad aumentada |
DK2729160T3 (da) | 2011-07-08 | 2019-07-01 | Aegerion Pharmaceuticals Inc | Manipulerede polypeptider, der har forbedret virkningstid og reduceret immunogenicitet |
JP6006309B2 (ja) | 2011-07-08 | 2016-10-12 | アミリン・ファーマシューティカルズ,リミテッド・ライアビリティ・カンパニーAmylin Pharmaceuticals,Llc | 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド |
-
2011
- 2011-09-28 ES ES11833075.2T patent/ES2630031T3/es active Active
- 2011-09-28 EP EP17163203.7A patent/EP3241558B1/en active Active
- 2011-09-28 PL PL17163203T patent/PL3241558T3/pl unknown
- 2011-09-28 CA CA2813087A patent/CA2813087C/en active Active
- 2011-09-28 DK DK17163203.7T patent/DK3241558T3/da active
- 2011-09-28 EP EP11833080.2A patent/EP2621519B1/en active Active
- 2011-09-28 BR BR122021020041-6A patent/BR122021020041B1/pt active IP Right Grant
- 2011-09-28 BR BR112013007385-3A patent/BR112013007385B1/pt active IP Right Grant
- 2011-09-28 EP EP11833075.2A patent/EP2621515B1/en active Active
- 2011-09-28 DK DK11833075.2T patent/DK2621515T3/en active
- 2011-09-28 JP JP2013531789A patent/JP2014502252A/ja active Pending
- 2011-09-28 CA CA3138758A patent/CA3138758A1/en active Pending
- 2011-09-28 BR BR112013007388-8A patent/BR112013007388B1/pt active IP Right Grant
- 2011-09-28 PT PT118330802T patent/PT2621519T/pt unknown
- 2011-09-28 EA EA201390497A patent/EA032917B1/ru unknown
- 2011-09-28 ES ES17163203T patent/ES2873253T3/es active Active
- 2011-09-28 CA CA2813038A patent/CA2813038C/en active Active
- 2011-09-28 EA EA201390474A patent/EA024507B1/ru unknown
- 2011-09-28 DK DK11833080.2T patent/DK2621519T3/en active
- 2011-09-28 ES ES11833080.2T patent/ES2641869T3/es active Active
- 2011-09-28 MX MX2013003482A patent/MX351128B/es active IP Right Grant
- 2011-09-28 CN CN201180056939.4A patent/CN103547590B/zh active Active
- 2011-09-28 WO PCT/US2011/053774 patent/WO2012050925A2/en active Application Filing
- 2011-09-28 CN CN201180057153.4A patent/CN103403019B/zh active Active
- 2011-09-28 JP JP2013531786A patent/JP6174489B2/ja active Active
- 2011-09-28 MX MX2013003472A patent/MX349054B/es active IP Right Grant
- 2011-09-28 EP EP17174544.1A patent/EP3305315A1/en not_active Withdrawn
- 2011-09-28 WO PCT/US2011/053786 patent/WO2012050930A2/en active Application Filing
- 2011-09-28 PT PT118330752T patent/PT2621515T/pt unknown
-
2013
- 2013-03-28 US US13/852,521 patent/US20130203661A1/en not_active Abandoned
- 2013-03-28 US US13/852,671 patent/US20130274182A1/en not_active Abandoned
-
2015
- 2015-05-04 US US14/703,523 patent/US10087228B2/en active Active
- 2015-07-15 US US14/800,537 patent/US20160137709A1/en not_active Abandoned
-
2016
- 2016-12-02 JP JP2016235165A patent/JP6608799B2/ja active Active
-
2017
- 2017-02-28 JP JP2017036849A patent/JP6412183B2/ja active Active
- 2017-06-28 CY CY20171100690T patent/CY1119023T1/el unknown
- 2017-09-26 CY CY20171101013T patent/CY1119498T1/el unknown
-
2019
- 2019-10-24 JP JP2019193539A patent/JP2020033366A/ja active Pending
-
2020
- 2020-01-24 US US16/751,538 patent/US11535659B2/en active Active
-
2022
- 2022-10-25 US US18/049,445 patent/US20230115655A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2641869T3 (es) | Polipéptidos de fusión de leptina-ABD con duración de acción aumentada | |
RU2528734C2 (ru) | Новый вариант эксендина и его конъюгат | |
ES2390270T3 (es) | Compuestos de GLP-1 unidos a polietilenglicol | |
ES2909074T3 (es) | Proteínas de fusión ELP para liberación controlada y sostenida | |
US9975940B2 (en) | Long-acting single-chain insulin analogues | |
ES2541633T3 (es) | Exendinas modificadas y usos de las mismas | |
RU2014101697A (ru) | Коагонисты рецепторов глюкагона/glp-1 | |
JP5908000B2 (ja) | 長期間作用性ペプチド類似体のための組成物 | |
KR101238979B1 (ko) | Peg화된 인슐린 리스프로 화합물 | |
JP6525471B2 (ja) | ヘプシジン類似体及びその使用 | |
ES2394218T3 (es) | Polipéptidos de fusión de GLP-1 (péptido 1 de tipo glucagón) con resistencia a la peptidasa aumentada | |
ES2572952T3 (es) | Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas | |
US20190375814A1 (en) | Biphasic single-chain insulin analogues | |
ES2898718T3 (es) | Método para preparar un complejo polipeptídico fisiológicamente activo | |
RU2014127270A (ru) | Аналог человеческого инсулина и его ацилированное производное | |
US20140249093A1 (en) | Carrier-Linked Prodrugs Having Reversible Carboxylic Ester Linkages | |
AU2013337250A1 (en) | Long-acting single-chain insulin analogues | |
US20220118053A1 (en) | Dry Pharmaceutical Formulations of CNP Conjugates | |
SG181648A1 (en) | Dry growth hormone composition transiently linked to a polymer carrier | |
KR102649941B1 (ko) | GLP1-Fc 융합 단백질 및 이의 접합체 | |
US20220119473A1 (en) | Acylated oxyntomodulin peptide analog | |
KR20230009499A (ko) | 연장된 시간 작용 아실화된 인슐린 화합물 | |
KR20230146040A (ko) | 글루카곤 유사 펩타이드-1 수용체 길항물질 | |
US20240058422A1 (en) | Glucagon-like peptide-1 receptor antagonists | |
BR112021005366A2 (pt) | análogo de insulina de cadeia simples, uso deste e método para reduzir o açúcar no sangue de um paciente |